Peer-reviewed veterinary case report
Pancreatic enzyme levels in cats with chronic kidney disease
By Panagiotis G. Xenoulis et al.·Published in Journal of Veterinary Internal Medicine·2021·Texas A&M University, College of Veterinary Medicine and Biomedical Sciences Gastrointestinal Laboratory College Station Texas USA, GB·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum feline pancreatic lipase immunoreactivity and trypsin‐like immunoreactivity concentrations in cats with experimentally induced chronic kidney disease
- Species:
- cat
Plain-English summary
A group of cats with chronic kidney disease (CKD) had their blood tested for pancreatic enzymes to see how kidney problems might affect these results. The study found that many of the cats with CKD had higher levels of a specific enzyme (fTLI) compared to healthy cats, which could complicate diagnosing pancreatic issues like exocrine pancreatic insufficiency (EPI). However, another enzyme (fPLI) remained stable and could still be used to diagnose pancreatitis in cats with kidney disease. More research is needed to confirm these findings in cats with naturally occurring CKD.
People also search for: cat kidney disease symptoms · cat pancreatitis diagnosis · elevated fTLI in cats · chronic kidney disease in cats · cat pancreatic enzyme levels
Abstract
Abstract Background Serum feline pancreatic lipase immunoreactivity (fPLI) and trypsin‐like immunoreactivity (fTLI) concentrations are commonly used in cats for the evaluation of pancreatic disease. The effect of kidney disease on these tests in cats are unknown. Objective To investigate the effect of experimentally induced chronic kidney disease (CKD) on serum fPLI and fTLI concentrations. Animals Surplus serum samples from 20 cats with CKD experimentally induced for an unrelated project and a group of healthy control cats. Methods Serum fTLI and fPLI concentrations were compared between groups. Results Mean (±SD) serum fTLI concentrations in 20 cats with CKD (117.8 ± 63.6 μg/L) were significantly higher than those in healthy cats (n = 32; 46.9 ± 17.5 μg/L; P < .0001). Serum fTLI concentrations in cats with CKD were above the upper limit of the reference interval in 13 of 20 cats (65%). Serum fPLI concentrations were not significantly different between cats with induced CKD (n = 18; 8.6 μg/L; range, 5.4‐9.9 μg/L) and healthy cats (n = 41; 7.4 μg/L; range, 5.0‐15.2 μg/L; P = .12). All cats with experimentally induced CKD had serum fPLI concentrations within the reference interval. Conclusions and Clinical Importance Decreased renal function has a clinically relevant impact on serum fTLI concentrations and potentially could interfere with a diagnosis of exocrine pancreatic insufficiency (EPI). Serum fPLI concentration was not affected by experimentally induced CKD and thus serum fPLI may be used for the diagnosis of pancreatitis in cats with kidney disease. Additional studies are needed to verify these results in cats with naturally occurring CKD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.1111/jvim.16296